Trilogy Capital’s Clorox CLX Stock Holding History

Trilogy Capital’s Portfolio CLX Stock Details CLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,800	Closed	-$565K	–	482
2017 Q4	$565K	Buy	+3,800	New	+$517K	0.09%	69

Other funds holding CLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CRC

Cedar Rock Capital London, United Kingdom $4.05B AUM 21.89% 1-Year Est. Return

VAM

ValueInvest Asset Management Luxembourg $1.47B AUM 0.87% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Trilogy Capital's CLX Position: Q1 2018 in Review

Trilogy Capital sold out of Clorox (CLX) in Q1 2018, closing a stake of 3,800 shares — an estimated $565K sold.

Trilogy Capital first reported a position in CLX in Q4 2017 and held it in 1 quarter. The position peaked at $565K in Q4 2017. 914 funds tracked by Wall St. Rank hold CLX as of Q1 2018.

Trilogy Capital reported no remaining Clorox position as of Q1 2018 after selling out during the quarter.
Trilogy Capital sold 3,800 Clorox shares in Q1 2018, an estimated $565K.
Trilogy Capital first reported a position in Clorox in Q4 2017 and held it in 1 quarter.
Trilogy Capital's Clorox position peaked at $565K in Q4 2017.
914 funds tracked by Wall St. Rank held Clorox as of Q1 2018.

Based on Trilogy Capital's 13F filing for Q1 2018, filed 24 May 2018.